Cellectis Acquires Vectocell Technology to Accelerate Therapeutic Development Programs
Cellectis S.A. announced that it has acquired the Vectocell® intracellular delivery technology from Diatos SA in order to optimize the efficacy of its drug candidates.
The Vectocell® technology platform can improve the performance of a therapeutic compound by enabling specific entry into the target cell compartment or organ in animals and humans. The technology is based on the fusion between the therapeutic protein and an antibody-derived peptide that facilitates passive entry into the cell. Experimental data show that this targeting technique provokes minimal immunogenicity, and thus offers excellent safety. Vectocell®'s ability to provide specific, targeted entry into any chosen cell type gives it a broad spectrum of applications.
"Vectocell® fits well with Cellectis' current molecular approaches and will slot into our portfolio perfectly. It has immediate applications in our two highest-priority activities: research tools and therapeutics ", commented Cellectis CEO André Choulika. "Vectocell® fused to a meganuclease will transform it in biotherapeutics".
The acquisition of Vectocell® will enrich Cellectis' intellectual property portfolio by an additional 9 patent families.
Other news from the department business & finance
